Beating the U.S. Department of Justice (DoJ) to the punch on the eve of a federal holiday weekend, Mylan NV announced a $465 million settlement late Friday to resolve potential state and federal lawsuits over its classification of its Epipen auto-injector as a generic for Medicaid rebate purposes.